|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
British Biologicals expands global operations
|
|
Saturday, 20 May, 2006, 08 : 00 AM [IST]
|
|
Nandita Vijay, Bangalore
|
ceutical leader in India is on a major expansion drive in the international markets. The company is entering Kenya, Cambodia, Nigeria and a few other countries in East Africa. This is primarily because of the growing demand for protein supplements in these countries.
The Rs 100 crore company with a growth rate of 40 per cent in FY 2005-06, will increase its focus in the global markets going by the potential demand for its range of products. It intends to increase its share from the current 5 per cent to 30 per cent. It is already present in Sri Lanka, West Indies, African region, Middle East, Malaysia, Philippines and Singapore where its range of nutraceuticals is doing well.
"Nutraceuticals are emerging to play a vital role in the nutrition of people throughout the world. In a scenario where health care costs are soaring, the protein supplements in powder form help to maintain health in people and prevent further deterioration, stated V Sridhar, executive director, British Biologicals.
Efforts are also on to enter the US and Europe markets in the future, but these will take time. However, the company is awaiting a clearance from the US for its documentation processes in manufacture.
Among the leading export products include Pro-Pl, a nutrition for pregnancy and lactation which contains Docosahexaenoic acid (DHA) and Gamma linolenic acid (GLA) vital for the baby's brain, vision and heart development, Kids Pro for children, B Protein - a supplement for nutrition, D Protein for diabetes and X-tra Mass for body building.
During 2005 end the company launched MediSlim, Kids Pro in water melon flavour and Ax Kal an artificial sweetener with sucralose. These are expected to give a big boost to the sales in the international market, he stated. Under the company's annual budget allocation for 2006-07, it has set aside Rs 1 crore for research and development activities which are statutory requirements during its global market expansion efforts.
In 2005, the company made an investment of Rs 1 crore to set up a second facility at Bannerghatta Road for the contract manufacture of products. The demand has been growing, stated Sridhar.
In the Indian market, the company holds a leadership status with its range of products, which are primarily marketed via the ethical route. Other players in India are Novartis, Abbot and Dumas.
|
|
|
|
|
|
|
|
|
|